The legal action follows a major setback for GRAIL on February 19, 2026, when the company revealed that its NHS-Galleri trial failed to reach a primary endpoint regarding the reduction of Stage III-IV cancer cases. Management cited a need for longer follow-up periods to adequately compare study arms, yet the market reaction was immediate and severe. Shares of the NASDAQ-listed firm plummeted by more than 50% following the announcement, wiping out significant value for shareholders.

Pomerantz LLP, a firm specializing in corporate and securities litigation, is representing the class. Investors who acquired GRAIL securities during the designated class period are encouraged to contact Danielle Peyton at 646-581-9980 or via email at dpeyton@pomlaw.com to provide details regarding their holdings. Further information regarding the complaint is available through the firm’s website.